不适合移植的大 B 细胞淋巴瘤二线使用 axicabtagene ciloleucel：ALYCANTE 最终分析
Second-line axicabtagene ciloleucel in large B-cell lymphoma ineligible for transplantation: ALYCANTE final analysis.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
体外弥漫大 B 细胞淋巴瘤细胞系模型：研究新型免疫治疗策略的工具
英文原题：In Vitro Diffuse Large B-Cell Lymphoma Cell Line Models as Tools to Investigate Novel Immunotherapeutic Strategies.
查看英文原题
In Vitro Diffuse Large B-Cell Lymphoma Cell Line Models as Tools to Investigate Novel Immunotherapeutic Strategies.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
尽管弥漫性大B细胞淋巴瘤（DLBCL）发病率较高，其治疗仍持续面临挑战。最常见的DLBCL变异类型包括活化B细胞样（ABC）和生发中心B细胞样（GCB）亚型，也包括MYC与BCL2/BCL6重排型DLBCL；不同类型对标准利妥昔单抗（RTX）方案化学免疫治疗的敏感性不同，临床结局也有差异。然而，约半数患者在一线治疗后仍会耐药或复发，亟需为这类患者开发新的个体化治疗策略。免疫治疗尤其具有吸引力，已在大量临床前和临床研究中得到探索。能够模拟原发肿瘤的患者来源细胞系，是推动临床前研究的重要工具。本文综述现有DLBCL细胞系模型及其在设计新型免疫治疗策略中的用途。
展开英文摘要原文
Despite the high incidence of diffuse large B-cell lymphoma (DLBCL), its management constitutes an ongoing challenge. The most common DLBCL variants include activated B-cell (ABC) and germinal center B-cell-like (GCB) subtypes including DLBCL with MYC and BCL2/BCL6 rearrangements which vary among each other with sensitivity to standard rituximab (RTX)-based chemoimmunotherapy regimens and lead to distinct clinical outcomes.
However, as first line therapies lead to resistance/relapse (r/r) in about half of treated patients, there is an unmet clinical need to identify novel therapeutic strategies tailored for these patients. In particular, immunotherapy constitutes an attractive option largely explored in preclinical and clinical studies.
Patient-derived cell lines that model primary tumor are indispensable tools that facilitate preclinical research. The current review provides an overview of available DLBCL cell line models and their utility in designing novel immunotherapeutic strategies.
论文信息
- 作者
- Kubacz M、Kusowska A、Winiarska M、Bobrowicz M
- 单位
- Department of Immunology, Medical University of Warsaw, 02-097 Warsaw, Poland.Poland
- 文献类型
- 综述
- 期刊
- Cancers2022 Dec 30
- 原文标识
- PubMed 36612228 · DOI 10.3390/cancers15010235
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →